Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### Patent and Trademark Office

          - [Docket No. PTO-P-2023-0049]

# AGENCY:

United States Patent and Trademark Office, Department of Commerce.

# ACTION:

Notice of interim patent term extension.

# SUMMARY:

The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 7,329,689 ('689 patent).

# FOR FURTHER INFORMATION CONTACT:

                        Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-0909 or                         *ali.salimi@uspto.gov;*                         or Josephine Chang, Legal Advisor, Office of Patent Legal Administration, at 571-270-3522 or                         *josephine.chang@uspto.gov.*

# SUPPLEMENTARY INFORMATION:

35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

                    On July 31, 2023, Italfarmaco SPA, the owner of record of the '689 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the '689 patent. The '689 patent claims the drug product known by the tradename DUVYZATTM                     (Givinostat hydrochloride monohydrate). The application for interim patent term extension indicates that the approval phase of the RRP, as described in 35 U.S.C. 156(g)(1)(B)(ii), began on April 21, 2023, for DUVYZATTM                     (Givinostat hydrochloride monohydrate) and is ongoing before the Food and Drug Administration for permission to market and use the product commercially.                

                    Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the '689 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears reasonable to expect the approval phase of the RRP to continue beyond the expiration date of the patent,                     *i.e.,*                     January 15, 2024, interim extension of the '689 patent's term under 35 U.S.C. 156(d)(5) is appropriate.                

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,329,689 is granted for a period of one year from the original expiration date of the '689 patent.

Brian Hanlon,

Acting Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2023-25697 Filed 11-20-23; 8:45 am]

BILLING CODE 3510-16-P